(Q37844338)

24 August 2017

1 reference

title

Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life (English)

1 reference

24 August 2017

0 references

0 references

1 reference

Malena Cohen-Cymberknoh

series ordinal

1

object named as

Malena Cohen-Cymberknoh

1 reference

24 August 2017

2

David Shoseyov

1 reference

24 August 2017

Eitan Kerem

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

17 February 2011

1 reference

American Journal of Respiratory and Critical Care Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

183

1 reference

24 August 2017

issue

11

1 reference

24 August 2017

page(s)

1463-1471

1 reference

Identification of the cystic fibrosis gene: genetic analysis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Identification of the cystic fibrosis gene: chromosome walking and jumping

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Molecular basis for the ATPase activity of CFTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Macromolecular interactions and ion transport in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Update on pathogenesis of cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cystic fibrosis mortality and survival in the UK: 1947-2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Composite Spirometric–Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Dornase alfa in early cystic fibrosis lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

The CF salt controversy: in vivo observations and therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Defining routes of airborne transmission of Pseudomonas aeruginosa in people with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Familial concordance of phenotype and microbial variation among siblings with CF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Pseudomonas aeruginosa biofilms in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Shifting patterns of inhaled antibiotic use in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cystic Fibrosis Pulmonary Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Exacerbations in cystic fibrosis: 3--Management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Exacerbations in cystic fibrosis: 2 . prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

The role of inflammation in the pathophysiology of CF lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

18F-fluorodeoxyglucose-PET/CT imaging of lungs in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Airway inflammation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Macrolide antibiotics and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

The role of azithromycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Effect of high-dose ibuprofen in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Evidence for newborn screening for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Wasting as an independent predictor of mortality in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Nutrition in patients with cystic fibrosis: a European Consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Consensus report on nutrition for pediatric patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Pancreatic enzyme replacement therapy for young cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Abnormal glucose metabolism in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Long-term effect of insulin treatment in cystic fibrosis-related diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Mild, moderate, and severe forms of allergic bronchopulmonary aspergillosis: a clinical and serologic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Gastroesophageal reflux in the infant with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Complications of gastroesophageal reflux in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Gastro-oesophageal reflux in infants under 6 months with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cystic fibrosis in Denmark 1945 to 1985. An analysis of incidence, mortality and influence of centralized treatment on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Early referral to cystic fibrosis specialist centre impacts on respiratory outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Standards of care for patients with cystic fibrosis: a European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Factors influencing outcomes in cystic fibrosis: a center-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Determinants of adherence in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Increasing adherence to cystic fibrosis treatment: a systematic review of behavioral techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Lung Function in Infants with Cystic Fibrosis Diagnosed by Newborn Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

Daily versus weekly azithromycin in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201009-1478CI

10.1164/RCCM.201009-1478CI

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference